PO.PS01.02 · 人群科学
哥伦比亚卡塔赫纳一家领先肿瘤机构中乳腺癌特征与诊断年龄的关系
Breast cancer characteristics in relation to age at diagnosis, in a leading oncology institution in Cartagena, Colombia
该海报暂无可下载的资料
AACR 官方页面
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景:乳腺癌是一项重大的公共卫生问题,是最常被诊断的恶性肿瘤,也是全球以及哥伦比亚女性癌症死亡的首要原因。生活在已完成转型国家的女性与转型中国家的女性相比,发病率显著更高,这反映了某些生殖风险因素(包括初潮年龄较早)的患病率更高。关于生活在发展中国家的乳腺癌患者临床特征的认识很匮乏。本研究评估并比较了在哥伦比亚一家肿瘤中心接受治疗的老年、中年和年轻女性乳腺癌病例的特征。目的:描述在哥伦比亚卡塔赫纳一家领先肿瘤机构接受治疗的乳腺癌病例的特征,及其与诊断时年龄的关联。
方法:回顾性分析了2010年1月至2024年12月间在哥伦比亚卡塔赫纳一家领先肿瘤机构接受乳腺癌治疗的女性数据库。比较了20至<40岁、40至<65岁和≥65岁女性之间的临床和组织病理学特征。收集的临床信息包括:初潮年龄、产次、诊断时分期和组织学类型。
结果:纳入698例患者,诊断时平均年龄为56.06岁(SD=±13.16,95%CI=55.08-57.04)。大多数病例为中年女性(40至65岁=63.33%),老年女性病例比例较高(>65岁=24.21%),年轻女性数量较少(20至39岁=10.45%)。观察到诊断年龄与初潮年龄(平均=12.09岁,SD=±1.69,95%CI=12.74-13.03)之间存在显著关联(p=0.0001,t检验);以及诊断年龄与妊娠次数(平均=3.25,SD=±2.13,95%CI=3.08-3.42)之间存在显著关联(p=0.0001,t检验)。大多数肿瘤(84.45%)为导管癌,其次为小叶癌(6.3%),其他组织学类型占比很小,组织学类型与年龄之间发现有统计学显著差异(p=0.041,Fisher检验)。57.11%的患者表现为局部晚期疾病(II期),仅5%表现为转移性疾病,年龄与诊断时临床分期之间存在显著关联(p=0.0099,X2)。
结论:这些发现凸显了诊断年龄、生殖因素和就诊时分期之间的显著关联,提示不同年龄组存在不同的风险模式。本研究队列中的大多数病例在诊断时表现为局部晚期疾病,支持在此环境中制定适应年龄和个体风险的筛查和照护策略的必要性。未来纳入分子分型和生存结局的研究,对于优化风险分层和为乳腺癌防控政策提供信息至关重要。
查看英文原文 English abstract
Background: Breast cancer is a major public health problem, it is the most commonly diagnosed malignant neoplasia, and the leading cause of cancer deaths in women, worlwide and also in Colombia. .Women living in transitioned countries have considerably higher incidence rates compared with those in transitioning countries, this reflects a higher prevalence of some reproductive risk factors, including early age at menarche. There is scarce knowledge about the clinical characteristics of breast cancer patients living in developing countries. This study, evaluated and compared the characteristics of breast cancer cases in older, middle aged, and young women, treated at an oncology center in Colombia.Objective: To describe the characteristics of breast cancer cases treated in a leading oncology institution in Cartagena, Colombia, and their association with the age at the time of diagnosis.
Methods: A database of women treated for breast cancer at a leading oncology institution in Cartagena, Colombia, between January 2010 and December 2024, was retrospectively analyzed. Were compared clinical and histopathological characteristics between women aged 20 to <40, 40 to <65, and ≥65 years. Clinical information was collected: age at menarche, parity, stage at diagnosis and histological type.
Results: Were included 698 patients with a mean age at diagnosis of 56.06 years (SD=±13.16, 95%CI= 55.08-57.04). Most of cases were middle-aged women (40 to 65 years= 63.33%) with a high proportion of cases in older women (>65 years= 24.21%), and a smaller number of young women (20 to 39 years=10.45%). Were observed significant associations between age at diagnosis and age of menarche (mean=12.09 years, SD=±1.69, 95%CI= 12.74-13.03), (p=0.0001, t test); and, between age at diagnosis and number of pregnancies (mean=3.25, SD=±2.13, 95%CI= 3.08-3.42), (p=0.0001, t test). Most of the tumors (84.45%) were ductal carcinomas, followed by lobular carcinomas (6.3%), and other histological types in small proportion, a statistically significant difference was found between histological type and age (p=0.041, Fisher´s test). Of the patients, 57.11% presented with locally advanced disease (stage II), only 5% presented with metastatic disease, and there was a significant association between age and clinical stage at diagnosis (p=0.0099, X2).
Conclusion: These findings highlight significant associations between age at diagnosis, reproductive factors, and stage at presentation, suggesting different risk patterns across age groups. Most of the cases in this study cohort presented locally advanced disease at the moment of diagnosis, supporting the need for screening and care strategies adapted to age and individual risk in this setting. Future studies incorporating molecular profiling and survival outcomes will be essential to refine risk stratification and inform breast cancer control policies.
利益披露 Disclosure
E. Ferreira, None..
L. Suarez, None..
M. P. Valera, None..
J. Aldana, None..
J. S. Diaz, None..
I. Benedetti, None.